ClinicalTrials.gg
CompletedNCT01889238Updated Dec 13, 2024Results posted

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

A Phase 2 interventional study of Enzalutamide in Advanced, Androgen Receptor Positive Triple Negative Breast Cancer, sponsored by Pfizer. Completed at 132 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing enzalutamide in Breast Neoplasms — 1 open to participants now, 3 under way, none of them phase 3. enzalutamide · Breast Neoplasms.

Enrollment
3rd of 13
118 · median 61
Started
2013
with 1 other
Phase 2
9 of 13
1 open now
Registered
2nd of 13
by date
Lead sponsor
4 of 13
Pfizer

Among the 13 studies testing enzalutamide in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 2, and was the 2nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 13 studies testing enzalutamide in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing enzalutamide in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor and are not Her2 amplified.

03

Conditions studied

  • Advanced, Androgen Receptor Positive Triple Negative Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • triple negative
  • androgen receptor positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women at least 18 years of age;
  • Advanced AR+ TNBC;
  • Availability of a representative tumor specimen:
  • Either or bone only nonmeasurable disease;
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Any severe concurrent disease, infection, or comorbid condition;
  • Any condition or reason that interferes with the patient's ability to participate in the trial, that may cause undue risk, or complicates the interpretation of safety data;
  • Current or previously treated or active ;
  • Current hormone replacement therapy;
  • Local palliative radiation therapy within 7 days before day 1;
  • History of another invasive cancer within 5 years of day 1;
  • \< 1500/µL, count \< 75,000/µL, or \< 9 g/dL (5.6 mmol/L) at the screening visit;
  • Creatinine > 1.5 times (ULN) at the screening visit;
  • History of seizure or any condition that may predispose to seizure;
  • cardiovascular disease;
  • Active gastrointestinal disorder affecting absorption;
  • Major surgery within 4 weeks before day 1;
  • Treatment with any commercially available anticancer agent within 14 days before day 1;
  • Treatment with any agent within 2 weeks before day 1;
  • Treatment with any of the following medications within 2 weeks before day 1: Estrogens, including hormone replacement therapy; Androgens (testosterone, dihydroepiandrosterone, etc);Systemic radionuclides (eg, samarium or strontium);Vaccine therapy;
  • Hypoglycemic episode requiring medical intervention while on insulin treatment within 12 months before day 1;
  • reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    160 mg administered as four 40 mg soft gelatin capsules orally once daily

    Drug: Enzalutamide

Interventions

  • 160 mg administered as four soft gelatin capsules orally once daily

    Also known as: Xtandi®, MDV3100

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population

    Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of complete response (CR), partial response(PR), stable disease(SD) for \>=16 weeks on radiologic imaging based on Investigator assessment using Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1). An estimate of the percentage and its exact 2-sided 85% confidence interval(CI) were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10mm short axis. PR: At least 30% decrease in sum of longest diameter (LD) of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

    Time frame: Week 16

  2. Percentage of Participants With Clinical Benefit at Week 16: Intent-to-Treat (ITT) Population

    Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of CR, PR, or SD for \>= 16 weeks on radiologic imaging based on Investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With Clinical Benefit at Week 24: Evaluable Population

    Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

    Time frame: Week 24

  2. Percentage of Participants With Clinical Benefit at Week 24: ITT Population

    Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

    Time frame: Week 24

  3. Percentage of Participants With Best Objective Response: Evaluable Population

    Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.

    Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)

  4. Percentage of Participants With Best Objective Response: ITT Population

    Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.

    Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)

  5. Progression-Free Survival (PFS): Evaluable Population

    PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

    Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)

  6. Progression-Free Survival: ITT Population

    PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

    Time frame: From Baseline up to disease progression or death due to any cause (up to 87 Weeks)

  7. Time to Response: Evaluable Population

    The time to response is defined as the time from the date of first dose of study drug to initial CR or PR. Participants without response of CR or PR before the data cutoff date were censored at the last tumor assessment date before the data cutoff. Kaplan-Meier method was used to summarize time to response.

    Time frame: From first dose of study drug until first documentation of CR or PR or data censoring date, whichever occurred first (up to 87 Weeks)

  8. Duration of Response: Evaluable Population

    Duration of objective response is defined as the time from initial CR or PR to documented disease progression or death due to any cause, whichever occurs first. Participants without disease progression or death due to any cause before the data cutoff date were censored at the last tumor assessment date before the data cutoff.

    Time frame: From first documentation of CR or PR until first documentation of tumor progression or death due to any cause or data censoring date, whichever occurred first (up to 87 Weeks)

  9. Number of Participants With Postbaseline Laboratory Toxicities Grade 3 or 4

    Laboratory parameters included hematology parameters \[low lymphocytes (10\^6/L), neutrophils (10\^6/L) and Leukocytes (10\^9/L)\] and chemistry parameters \[high phosphate (mmol/L), bilirubin, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with postbaseline laboratory toxicity Grade 3 or 4 as per NCI-CTCAE (version 4.0) (Grade 3= Severe, Grade 4= Life-threatening) were reported.

    Time frame: From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)

Other outcomes

  1. Trough Plasma Concentration of Enzalutamide and Its Metabolite

    M2 was the metabolite of enzalutamide. The lower limit of quantitation (LLQ) was 0.0200 micrograms per milliliter (mcg/mL) for enzalutamide and M2.

    Time frame: Predose on Day 1 (Baseline), Week 9 and Week 17

  2. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events that were absent before treatment or that worsened relative to pretreatment state between first dose of study drug and up to 30 days after last dose of study drug or the day prior to initiation of new anti-tumor treatment. AEs included both serious and non-serious AEs.

    Time frame: Baseline up to 87 weeks

  3. Number of Participants With Study Drug Discontinuation Due to Adverse Events

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Data reported here is for study drug discontinuation due to adverse events.

    Time frame: Baseline up to 87 weeks

  4. Number of Participants With Grade 3 or Higher Adverse Events

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. As per the NCI CTCAE, version 4.0, Grade 3= severe, Grade 4= life-threatening and Grade 5= death. Only the participants with treatment-emergent AEs of Grade 3 (severe) or higher grade were reported in this outcome measure.

    Time frame: Baseline up to 87 weeks

  5. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Criteria: Systolic blood pressure (SBP):absolute SBP\<90 millimeters of mercury (mmHg) and decrease from baseline (DFB)\>30mmHg, absolute SBP\>180mmHg and increase from baseline (IFB)\>40 mmHg, final visit (FV) or 2 consecutive visits (CV) SBP\>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP\>=140mmHg, most extreme post- baseline SBP\>=180mmHg, most extreme SBP\>=140mmHg and\>=20 mmHg CFB, most extreme SBP\>=180mmHg and\>=20mmHg CFB; diastolic blood pressure (DBP): absolute DBP\>105mmHg and IFB\>30mmHg, absolute DBP\<50mmHg and DFB\>20mmHg, final visit or 2 consecutive visits DBP\>=15mmHg CFB, most extreme post-baseline DBP\>=90mmHg, most extreme post-baseline DBP\>=105mmHg, most extreme DBP\>=90mmHg and\>=15mmHg CFB, most extreme DBP\>=105mmHg and\>=15mmHg CFB; heart rate\<50beats per minute (BPM) and DFB\>20BPM or heart rate\>120BPM and IFB\>30BPM. Only those categories, in which at least 1 participant had data were reported.

    Time frame: From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)

  6. Number of Participants With Change From Baseline in Laboratory Parameters Grades by 2 or More Grades

    Laboratory tests included hematology parameters \[low lymphocytes (10\^6/L), white blood cells (10\^9/L), neutrophils (10\^6/L), hemoglobin gram per Liter(g/L) and platelets (10\^9/L)\] and chemistry parameters \[mean albumin grams per Liter(g/L), calcium milli mole per Liter(mmol/L), Phosphate (mmol/L), alanine aminotransferase units per Liter(U/L), Aspartate aminotransferase (U/L), bilirubin micro mole per Liter, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with change from baseline in laboratory parameters Grades by 2 or More Grades as per NCI-CTCAE (version 4.0) (Grade 2=Moderate, Grade 3= Severe, Grade 4= Life-threatening) were reported.

    Time frame: From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)

07

Results

Posted Aug 22, 2018

Participant flow

Total of 118 participants with advanced androgen receptor positive (AR+) and triple-negative breast cancer (TNBC) were enrolled at total of 34 study sites in North America and Europe to attain total of 78 evaluable participants.

Participant flow — Overall Study
MilestoneEnzalutamide
Started118
Completed0
Not completed118
Withdrew: Death1
Withdrew: Withdrawal by subject1
Withdrew: Adverse event6
Withdrew: Disease progression104
Withdrew: Other6

Outcome measures

PrimaryPercentage of Participants With Clinical Benefit at Week 16: Evaluable Population

Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of complete response (CR), partial response(PR), stable disease(SD) for \>=16 weeks on radiologic imaging based on Investigator assessment using Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1). An estimate of the percentage and its exact 2-sided 85% confidence interval(CI) were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10mm short axis. PR: At least 30% decrease in sum of longest diameter (LD) of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population
Percentage of participantsEnzalutamide
Percentage of Participants With Clinical Benefit at Week 16: Evaluable Population33.3 (25.53 to 41.63)
PrimaryPercentage of Participants With Clinical Benefit at Week 16: Intent-to-Treat (ITT) Population

Percentage of participants with a clinical benefit at Week 16 defined as percentage of participants with a best response of CR, PR, or SD for \>= 16 weeks on radiologic imaging based on Investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit at Week 16: Intent-to-Treat (ITT) Population
Percentage of participantsEnzalutamide
Percentage of Participants With Clinical Benefit at Week 16: Intent-to-Treat (ITT) Population24.6 (18.98 to 30.88)
SecondaryPercentage of Participants With Clinical Benefit at Week 24: Evaluable Population

Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit at Week 24: Evaluable Population
Percentage of participantsEnzalutamide
Percentage of Participants With Clinical Benefit at Week 24: Evaluable Population28.2 (21.04 to 36.48)
SecondaryPercentage of Participants With Clinical Benefit at Week 24: ITT Population

Percentage of participants with a clinical benefit at Week 24 defined as percentage of participants with a best response of CR, PR, or SD for \>= 24 weeks on radiologic imaging based on investigator assessment using RECIST 1.1. An estimate of the percentage and its exact 2-sided 85% CI were calculated using the Blaker method. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in size \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during the study as a reference.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit at Week 24: ITT Population
Percentage of participantsEnzalutamide
Percentage of Participants With Clinical Benefit at Week 24: ITT Population20.3 (15.16 to 26.21)
SecondaryPercentage of Participants With Best Objective Response: Evaluable Population

Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.

Time frame:
From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Objective Response: Evaluable Population
Percentage of participantsEnzalutamide
Percentage of Participants With Best Objective Response: Evaluable Population8.5 (3.05 to 12.02)
SecondaryPercentage of Participants With Best Objective Response: ITT Population

Percentage of participants with best objective response defined as percentage of participants with a best response of CR and PR based on investigator assessment of target, non-target and new lesions using RECIST 1.1. As per RECIST 1.1, CR defined as disappearance of all target, non-target lesions and normalization of tumor marker level and all lymph nodes decreased to non-pathological in \<10 mm short axis. PR: At least 30% decrease in sum of LD of target lesions taking as reference baseline sum of LD, without progression of non-target lesions, no appearance of new lesions.

Time frame:
From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With Best Objective Response: ITT Population
Percentage of participantsEnzalutamide
Percentage of Participants With Best Objective Response: ITT Population6.2 (2.80 to 8.95)
SecondaryProgression-Free Survival (PFS): Evaluable Population

PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

Time frame:
From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Reported as:
Median · Weeks
Progression-Free Survival (PFS): Evaluable Population
WeeksEnzalutamide
Progression-Free Survival (PFS): Evaluable Population14.3 (8.3 to 16.1)
SecondaryProgression-Free Survival: ITT Population

PFS was defined as the time (in weeks) from the date of first dose of study drug to the date of documented disease progression or death due to any cause whichever occurs first as determined by the investigator using RECIST 1.1. As per RECIST 1.1, progression was defined as: \>=20 percent increase in sum of LD of target lesions taking as a reference the smallest sum of the LD recorded since the treatment started, or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions.

Time frame:
From Baseline up to disease progression or death due to any cause (up to 87 Weeks)
Reported as:
Median · Weeks
Progression-Free Survival: ITT Population
WeeksEnzalutamide
Progression-Free Survival: ITT Population12.6 (8.1 to 15.1)
Other pre-specifiedTrough Plasma Concentration of Enzalutamide and Its Metabolite

M2 was the metabolite of enzalutamide. The lower limit of quantitation (LLQ) was 0.0200 micrograms per milliliter (mcg/mL) for enzalutamide and M2.

Time frame:
Predose on Day 1 (Baseline), Week 9 and Week 17
Reported as:
Geometric mean · mcg/mL
Trough Plasma Concentration of Enzalutamide and Its Metabolite
mcg/mLEnzalutamide
Enzalutamide: Day 1NA ± NA
M2: Day 1NA ± NA
Enzalutamide: Week 912.59 ± 33.46
M2: Week 913.48 ± 35.64
Enzalutamide: Week 1712.79 ± 37.33
M2: Week 1713.88 ± 25.47
Other pre-specifiedNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent are events that were absent before treatment or that worsened relative to pretreatment state between first dose of study drug and up to 30 days after last dose of study drug or the day prior to initiation of new anti-tumor treatment. AEs included both serious and non-serious AEs.

Time frame:
Baseline up to 87 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEnzalutamide
Treatment emergent adverse events109
Treatment emergent serious adverse events29
Other pre-specifiedNumber of Participants With Study Drug Discontinuation Due to Adverse Events

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Data reported here is for study drug discontinuation due to adverse events.

Time frame:
Baseline up to 87 weeks
Reported as:
Count of participants · Participants
Number of Participants With Study Drug Discontinuation Due to Adverse Events
ParticipantsEnzalutamide
Number of Participants With Study Drug Discontinuation Due to Adverse Events8
Other pre-specifiedNumber of Participants With Grade 3 or Higher Adverse Events

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. As per the NCI CTCAE, version 4.0, Grade 3= severe, Grade 4= life-threatening and Grade 5= death. Only the participants with treatment-emergent AEs of Grade 3 (severe) or higher grade were reported in this outcome measure.

Time frame:
Baseline up to 87 weeks
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher Adverse Events
ParticipantsEnzalutamide
Number of Participants With Grade 3 or Higher Adverse Events36
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Criteria: Systolic blood pressure (SBP):absolute SBP\<90 millimeters of mercury (mmHg) and decrease from baseline (DFB)\>30mmHg, absolute SBP\>180mmHg and increase from baseline (IFB)\>40 mmHg, final visit (FV) or 2 consecutive visits (CV) SBP\>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP\>=140mmHg, most extreme post- baseline SBP\>=180mmHg, most extreme SBP\>=140mmHg and\>=20 mmHg CFB, most extreme SBP\>=180mmHg and\>=20mmHg CFB; diastolic blood pressure (DBP): absolute DBP\>105mmHg and IFB\>30mmHg, absolute DBP\<50mmHg and DFB\>20mmHg, final visit or 2 consecutive visits DBP\>=15mmHg CFB, most extreme post-baseline DBP\>=90mmHg, most extreme post-baseline DBP\>=105mmHg, most extreme DBP\>=90mmHg and\>=15mmHg CFB, most extreme DBP\>=105mmHg and\>=15mmHg CFB; heart rate\<50beats per minute (BPM) and DFB\>20BPM or heart rate\>120BPM and IFB\>30BPM. Only those categories, in which at least 1 participant had data were reported.

Time frame:
From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsEnzalutamide
SBP:Most extreme SBP>=140 mmHg and>=20 mmHg CFB12
SBP: absolute SBP <90 mmHg and DFB>30 mmHg1
SBP: Most extreme post baseline SBP >=140 mmHg42
SBP: Most extreme post baseline SBP >=180 mmHg1
DBP:Most extreme DBP>=90 mmHg and>=15 mmHg CFB12
DBP:Most extreme DBP>=105 mmHg and>=15 mmHg CFB2
DBP: Most extreme post baseline result >=90 mmHg24
DBP: Most extreme post baseline result >=105 mmHg4
Other pre-specifiedNumber of Participants With Change From Baseline in Laboratory Parameters Grades by 2 or More Grades

Laboratory tests included hematology parameters \[low lymphocytes (10\^6/L), white blood cells (10\^9/L), neutrophils (10\^6/L), hemoglobin gram per Liter(g/L) and platelets (10\^9/L)\] and chemistry parameters \[mean albumin grams per Liter(g/L), calcium milli mole per Liter(mmol/L), Phosphate (mmol/L), alanine aminotransferase units per Liter(U/L), Aspartate aminotransferase (U/L), bilirubin micro mole per Liter, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with change from baseline in laboratory parameters Grades by 2 or More Grades as per NCI-CTCAE (version 4.0) (Grade 2=Moderate, Grade 3= Severe, Grade 4= Life-threatening) were reported.

Time frame:
From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Laboratory Parameters Grades by 2 or More Grades
ParticipantsEnzalutamide
Hematology: Hemoglobin1
Hematology: Leukocytes4
Hematology: Lymphocytes12
Hematology: Neutrophils2
Hematology: Platelets1
Chemistry: Alanine aminotransferase1
Chemistry: Albumin4
Chemistry: Alkaline phosphatase5
Chemistry: Bilirubin2
Chemistry: Calcium2
Chemistry: Glucose5
Chemistry: Phosphate4
Chemistry: Aspartate Aminotransferase1
SecondaryTime to Response: Evaluable Population

The time to response is defined as the time from the date of first dose of study drug to initial CR or PR. Participants without response of CR or PR before the data cutoff date were censored at the last tumor assessment date before the data cutoff. Kaplan-Meier method was used to summarize time to response.

Time frame:
From first dose of study drug until first documentation of CR or PR or data censoring date, whichever occurred first (up to 87 Weeks)
Reported as:
Median · Weeks
Time to Response: Evaluable Population
WeeksEnzalutamide
Time to Response: Evaluable PopulationNA (NA to NA)
SecondaryDuration of Response: Evaluable Population

Duration of objective response is defined as the time from initial CR or PR to documented disease progression or death due to any cause, whichever occurs first. Participants without disease progression or death due to any cause before the data cutoff date were censored at the last tumor assessment date before the data cutoff.

Time frame:
From first documentation of CR or PR until first documentation of tumor progression or death due to any cause or data censoring date, whichever occurred first (up to 87 Weeks)
Reported as:
Median · Weeks
Duration of Response: Evaluable Population
WeeksEnzalutamide
Duration of Response: Evaluable PopulationNA (NA to NA)
SecondaryNumber of Participants With Postbaseline Laboratory Toxicities Grade 3 or 4

Laboratory parameters included hematology parameters \[low lymphocytes (10\^6/L), neutrophils (10\^6/L) and Leukocytes (10\^9/L)\] and chemistry parameters \[high phosphate (mmol/L), bilirubin, Alkaline phosphatase (U/L) and glucose (mmol/L)\]. Number of participants with postbaseline laboratory toxicity Grade 3 or 4 as per NCI-CTCAE (version 4.0) (Grade 3= Severe, Grade 4= Life-threatening) were reported.

Time frame:
From start of study treatment on Day 1 up to 30 days after the last dose of study drug (up to maximum of 9.6 years)
Reported as:
Count of participants · Participants
Number of Participants With Postbaseline Laboratory Toxicities Grade 3 or 4
ParticipantsEnzalutamide
Hematology: Leukocytes1
Hematology: Lymphocytes9
Hematology: Neutrophils1
Chemistry: Alkaline Phosphatase1
Chemistry: Bilirubin1
Chemistry: Glucose4
Chemistry: Phosphate1

Adverse events

Collected over Baseline up to 87 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide88/118 (74.6%)29/118 (24.6%)106/118 (89.8%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventEnzalutamide
Disease progressionGeneral disorders3/118
Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/118
Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/118
Pleural effusionRespiratory, thoracic and mediastinal disorders3/118
Pericardial effusionCardiac disorders2/118
ConstipationGastrointestinal disorders2/118
Lung infectionInfections and infestations2/118
SepsisInfections and infestations2/118
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/118
Spinal cord compressionNervous system disorders2/118
Most frequent other events
Showing 10 of 27
Most frequent other events
EventEnzalutamide
FatigueGeneral disorders49/118
NauseaGastrointestinal disorders40/118
Decreased appetiteMetabolism and nutrition disorders22/118
DiarrhoeaGastrointestinal disorders18/118
ArthralgiaMusculoskeletal and connective tissue disorders18/118
ConstipationGastrointestinal disorders17/118
Back painMusculoskeletal and connective tissue disorders17/118
HeadacheNervous system disorders17/118
InsomniaPsychiatric disorders17/118
DyspnoeaRespiratory, thoracic and mediastinal disorders13/118

Baseline characteristics

Intent-to-treat (ITT) population included all enrolled participants who had positive androgen receptor (AR+) breast cancer as assessed by central review and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Enzalutamide
Mean58.3 ± 12.95
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide
Female118
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enzalutamide
Hispanic or Latino4
Not Hispanic or Latino108
Unknown or Not Reported6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enzalutamide
American Indian or Alaska Native1
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American20
White91
More than one race0
Unknown or Not Reported0
08

Study locations

132 sites
  • Rocky Mountain Cancer Centers
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Center Sky Ridge
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer Centers
    Lone Tree, Colorado 80124, United States
  • Florida Cancer Specialists
    Altamonte Springs, Florida 32701, United States
  • Florida Cancer Specialists
    Bonita Springs, Florida 34135, United States
  • Florida Cancer Specialists
    Bradenton, Florida 34209, United States
  • Florida Cancer Specialists
    Brandon, Florida 33511, United States
  • Florida Cancer Specialists
    Cape Coral, Florida 33914, United States
  • Florida Cancer Specialists
    Clearwater, Florida 33761, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33905, United States
  • Florida Cancer Specialist South Division
    Fort Myers, Florida 33908, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33908, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists
    Gainesville, Florida 32605, United States
  • Florida Cancer Specialists
    Hudson, Florida 34667, United States
  • Florida Cancer Specialists
    Largo, Florida 33770, United States
  • Florida Cancer Specialists
    Naples, Florida 34102, United States
  • Florida Cancer Specialists
    New Port Richey, Florida 34655, United States
  • Florida Cancer Specialists
    Orange City, Florida 32763, United States
  • Florida Cancer Specialists
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists
    Spring Hill, Florida 34608, United States
  • Florida Cancer Specialists
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists
    Venice, Florida 34285, United States
  • Florida Cancer Specialists
    Venice, Florida 34292, United States
  • Northwestern Medical Faculty Foundation(NMFF)/ Women's Cancer Center Shared Laboratories
    Chicago, Illinois 60611, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center, Investigational Drug Service Department of Pharmacy
    Chicago, Illinois 60637, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
    New Lenox, Illinois 60451, United States
  • Indiana University Health Hospital
    Indianapolis, Indiana 46202, United States
  • Indiana University Health Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Investigational Drug Services
    Indianapolis, Indiana 46202, United States
  • Sidney and Lois Eskenazi Hospital
    Indianapolis, Indiana 46202, United States
  • Springmill Medical Clinic
    Indianapolis, Indiana 46290, United States
  • Oncology Hematology Care, Inc.
    Crestview Hills, Kentucky 41017, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • The West Clinic, PC
    Corinth, Mississippi 38834, United States
  • The West Clinic, PC
    Southaven, Mississippi 38671, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University Infusion Center Pharmacy
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Siteman Cancer Center-South County
    Saint Louis, Missouri 63129, United States
  • Siteman Cancer Center-West County
    Saint Louis, Missouri 63141, United States
  • Siteman Cancer Center
    Saint Peters, Missouri 63376, United States
  • Hematology Oncology Associates of Northern NJ
    Morristown, New Jersey 07962, United States
  • Memorial Sloan Kettering - I Chemotherapy Practice/Investigational Drug Service
    New York, New York 10065, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Cone Health Cancer Center
    Greensboro, North Carolina 27403, United States
  • Wesley Long Community Hospital
    Greensboro, North Carolina 27403, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45211, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45219, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45230, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45236, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • Oncology Hematology Care, Inc.
    Fairfield, Ohio 45014, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • Greenville Health System
    Seneca, South Carolina 29672, United States
  • Greenville Health System
    Spartanburg, South Carolina 29307, United States
  • Tennessee Oncology, PLLC
    Dickson, Tennessee 37055, United States
  • Tennessee Oncology, PLLC
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology, PLLC
    Gallatin, Tennessee 37066, United States
  • Tennessee Oncology, PLLC
    Hermitage, Tennessee 37076, United States
  • Tennessee Oncology, PLLC
    Lebanon, Tennessee 37087, United States
  • Tennessee Oncology, PLLC
    Lebanon, Tennessee 37090, United States
  • The West Clinic, PC
    Memphis, Tennessee 38104, United States
  • The West Clinic, PC
    Memphis, Tennessee 38120, United States
  • Tennessee Oncology, PLLC
    Murfreesboro, Tennessee 37129, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt Breast Center at One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Vanderbilt Health Pharmacy One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37205, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37207, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37211, United States
  • Henry-Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • Tennessee Oncology, PLLC
    Smyrna, Tennessee 37167, United States
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology - Memorial City
    Houston, Texas 77024, United States
  • Texas Oncology - Longview Cancer Center
    Longview, Texas 75601, United States
  • Texas Oncology-Tyler
    Tyler, Texas 75702, United States
  • Virginia Cancer Institute
    Mechanicsville, Virginia 23116-1844, United States
  • Virginia Cancer Institute
    Midlothian, Virginia 23114, United States
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23235-4730, United States
  • Virginia Oncology Associates
    Virginia Beach, Virginia 23456, United States
  • UZA
    Edegem, Antwerpen 2650, Belgium
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • British Columbia Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
  • McGill University Health Centre-Cedars Cancer Centre
    Montreal, Quebec H4A 3J1, Canada

Showing the first 100 of 132 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. PubMed 29373071 ↗
  • Kumar V, Yu J, Phan V, Tudor IC, Peterson A, Uppal H. Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer. JCO Precis Oncol. 2017 Nov;1:1-19. doi: 10.1200/PO.17.00075. PubMed 35172518 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Mar 2015, 20 months.

Results were first posted in Aug 2018, 3 years 5 months after primary completion. A results delay was requested in Mar 2016.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 20 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jun 28, 2013
StartActual
Jun 12, 2013
Primary completionActual
Mar 1, 2015
CompletionActual
Jan 10, 2024
Results delay requested
Mar 21, 2016
Results first posted
Aug 22, 2018
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01889238
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Jun 28, 2013
Start date
Jun 12, 2013
Primary completion
Mar 1, 2015
Completion
Jan 10, 2024
Results posted
Aug 22, 2018
Last update
Dec 13, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
Pfizer CT.gov Call Center
study chair · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion